Janux Therapeutics, Inc.
General ticker "JANX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.8B (TTM average)
Janux Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -21.0%.
Estimated limits based on current volatility of 1.9%: low 14.95$, high 15.53$
Factors to consider:
- Total employees count: 81 (+26.6%) as of 2024
- Top business risk factors: Limited operating history, Profitability concerns, Regulatory and compliance, Economic downturns and volatility, Labor/talent shortage/retention
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [8.14$, 21.89$]
- 2026-12-31 to 2027-12-31 estimated range: [7.06$, 18.96$]
Financial Metrics affecting the JANX estimates:
- Negative: with PPE of -7.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -9.45 <= 0.07
- Positive: Shareholder equity ratio, % of 95.53 > 64.25
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
Short-term JANX quotes
Long-term JANX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $8.08MM | $10.59MM | $10.00MM |
| Operating Expenses | $81.06MM | $109.44MM | $167.67MM |
| Operating Income | $-72.98MM | $-98.85MM | $-157.67MM |
| Non-Operating Income | $14.69MM | $29.85MM | $44.04MM |
| R&D Expense | $54.92MM | $68.39MM | $125.90MM |
| Income(Loss) | $-58.29MM | $-68.99MM | $-113.62MM |
| Profit(Loss)* | $-58.29MM | $-68.99MM | $-227.25MM |
| Stockholders Equity | $344.35MM | $1,022.78MM | $956.82MM |
| Assets | $380.41MM | $1,061.52MM | $1,001.57MM |
| Operating Cash Flow | $-50.58MM | $-43.81MM | $-82.23MM |
| Capital expenditure | $1.85MM | $0.36MM | $1.04MM |
| Investing Cash Flow | $-41.19MM | $-258.02MM | $-300.98MM |
| Financing Cash Flow | $59.55MM | $713.24MM | $4.95MM |
| Earnings Per Share** | $-1.32 | $-1.28 | $-3.67 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.